Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

About NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office is the TTIPO that assists partnering with the NIAID.

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebo...

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

Contact NIAID Technology Transfer and Intellectual Property Office

Phone Number
301-496-2644

More About NIAID Technology Transfer and Intellectual Property Office

Therapeutic Areas
  • Autoimmune disorders
  • Infectious
  • Inflammation
Technologies
  • Antimicrobial
  • Biologics
  • Diagnostics
  • Nucleic acids
  • Peptides
  • Small molecules
  • Vaccines
Company Type
  • Public/Non-profit organisation
State of Ownership
  • Public
Sponsor content

Collaborative Research and Licensing Opportunity: Monoclonal Antibody Specific for DNA/RNA Hybrid Molecules

NIAID has a hybridoma available for non-exclusive licensing that produces a monoclonal antibody specific for DNA/RNA hybrids. The applications for this hybridoma include its use in immuno-fluorescence (IF) microscopy; DNA/RNA immunoprecipitation (DRIP) and also in diagnostic kits for viral/bacterial infections, cancers, and a variety of other human diseases. NIH researchers have also incorporated the antibody into a micro-array platform, expanding its potential for use in diagnostic devices.
Sponsor content

Collaborative Research and Licensing Opportunity: Neutralizing Antibodies to Influenza HA and Their Use and Identification

Scientists at NIAID isolated families of antibodies capable of neutralizing diverse group 1 and group 2 influenza A viruses. The antibodies identified precisely targeted parts of the hemagglutinin (HA) protein, present on the surface of the influenza virus, that are least variable from season to season. A passive administration of members of these families of antibodies to individuals would represent an alternative to the current standard of care for severe influenza virus infection.
Sponsor content

Collaborative Research and Licensing Opportunity: PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE

Inventors at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases have developed a novel CoV S protein vaccine antigen. This technology employs protein engineering to stabilize S in its prefusion conformation, preventing structural rearrangement, and exposing antigenically preferable surfaces. The technology has been applied to several CoV spikes, including those from human-relevant viruses, such as HKU1-CoV, SARS-CoV, and MERS-CoV. Particularly for MERS-COV, stabilized S proteins have been shown to elicit superior neutralizing antibody responses up to 10-fold higher in animal models and protect mice against lethal MERS-CoV infection.
Sponsor content

Collaborative Research and Licensing Opportunity: Novel Multivalent Nanoparticle Vaccines

Scientists at NIAID’s Vaccine Research Center are developing an alternative approach for design and production of seasonal influenza vaccines. The design includes recombinant fusion proteins that self-assemble into nanoparticles, referred to as mosaic nanoparticles, with influenza antigenic proteins displayed on the nanoparticle surface. Further engineering these recombinant fusion proteins, the scientists have developed nanoparticles that simultaneously display multiple strains of influenza viral protein antigens (the receptor-binding domain of hemagglutinin) on their surface.
Sponsor content

Collaborative Research and Licensing Opportunity: Stabilized Influenza Hemagglutinin Stem Region Trimers and Uses Thereof

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID) are developing immunogens which elicit neutralizing antibodies to the highly conserved stem region of the influenza viral protein hemagglutinin. By targeting this highly conserved region, which is nearly identical in various strains of influenza virus, these immunogens could train the immune system to defend against a wide variety of influenza strains including pandemic strains derived from animal reservoirs.
Sponsor content

Collaborative Research and Licensing Opportunity for a Research Material: A Potent, Broadly-neutralizing, Anti-HIV Antibody (35O22) that Binds a Novel Epitope

35O22 is a potent anti-HIV antibody that binds a novel HIV epitope. This antibody neutralizes at least 80% of HIV isolates tested so far. The unique binding of 35O22 makes it an attractive candidate to combine with other HIV antibodies or antivirals in treating or preventing HIV infection.
Sponsor content

Collaborative Research and Licensing Opportunity: HIV targets CD62L on central memory T cells through viral envelope glycans for adhesion and induces selectin shedding for viral release

NIAID researchers have shown that inhibition of CD62L shedding dramatically reduced HIV-1 infection and viral release from both viremic and aviremic CD4+ T cells. Therefore, inhibitors for CD62L sheddase can function as an anti-HIV treatment that may be effective alone or in combination with existing therapeutics.
Sponsor content

Collaborative Research and Licensing Opportunity: Broadly Neutralizing Antibodies against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein

Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal antibodies can be used as a therapeutic to: (1) treat an HIV infection, (2) decrease and prevent HIV-transmission from mother to infant, and (3) be effectively combined with anti-retroviral drug therapy.
Sponsor content

A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine

This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin.
Sponsor content

Collaborative Research and Licensing Opportunity: Inhibition of host heme oxygenase-1 as an adjunctive treatment to improve the outcome of conventional antibiotic chemotherapy of Mycobacterium tuberculosis (Mtb) infection.

Inhibition of host HO-1 reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control.